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Background: Hereditary spastic paraplegias (HSPs) are characterised by lower limb spasticity due to degeneration
of the corticospinal tract. We set out for an electrophysiological characterisation of motor and sensory tracts in
patients with HSP.
Methods: We clinically and electrophysiologically examined a cohort of 128 patients with genetically confirmed or
clinically probable HSP. Motor evoked potentials (MEPs) to arms and legs, somato-sensory evoked potentials of
median and tibial nerves, and nerve conduction studies of tibial, ulnar, sural, and radial nerves were assessed.
Results: Whereas all patients showed clinical signs of spastic paraparesis, MEPs were normal in 27% of patients and
revealed a broad spectrum with axonal or demyelinating features in the others. This heterogeneity can at least in
part be explained by different underlying genotypes, hinting for distinct pathomechanisms in HSP subtypes. In the
largest subgroup, SPG4, an axonal type of damage was evident. Comprehensive electrophysiological testing
disclosed a more widespread affection of long fibre tracts involving peripheral nerves and the sensory system in
40%, respectively. Electrophysiological abnormalities correlated with the severity of clinical symptoms.
Conclusions: Whereas HSP is primarily considered as an upper motoneuron disorder, our data suggest a more
widespread affection of motor and sensory tracts in the central and peripheral nervous system as a common
finding in HSP. The distribution patterns of electrophysiological abnormalities were associated with distinct HSP
genotypes and could reflect different underlying pathomechanisms. Electrophysiological measures are independent
of symptomatic treatment and may therefore serve as a reliable biomarker in upcoming HSP trials.
Keywords: Hereditary spastic paraplegia (HSP), Electrophysiology, Motor evoked potential (MEP), Somato-sensory
evoked potential (SSEP), NeurographyBackground
Hereditary spastic paraplegias (HSPs) encompass a group
of neurodegenerative disorders with lower limb spasticity
due to degeneration of the corticospinal tract as most
prominent sign. In addition to this “pure” form, additional
neurological and non-neurological symptoms, such as
mental retardation, dementia, epilepsy, cerebellar signs,
extrapyramidal symptoms, sensory deficits, peripheral* Correspondence: ludger.schoels@uni-tuebingen.de
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reproduction in any medium, provided the orneuropathy, skin and skeletal abnormalities can be present
(“complicated” forms) [1-4]. HSP is a rare disease with a
prevalence of ~ 2–10: 100,000 inhabitants [5,6]. To date,
more than 50 loci (SPG1 – SPG57) and more than 30
genes have been described [7].
Electrophysiological features of HSP have been studied
in rather small cohorts (maximum of 26 patients per
study) with poor genetic characterisation. Motor evoked
potentials were found to be abnormal to the legs in the
majority of patients and to the arms in up to one third of
patients [8-11]. Central and peripheral sensory tracts were
affected to very variable degrees [9,12-14]. First resultsd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stimulation in the largest HSP subgroup, SPG4 [15,16].
To analyse the spread of long fibre tract affection in
HSP and to explore potential effects of different pathome-
chanisms in distinct genotypes we studied motor and sen-
sory involvement of the central and peripheral nervous
system by clinical and electrophysiological means in a rep-
resentative cohort of HSP patients.
Methods
Patients
128 patients (58 women, 70 men) from 109 families were
recruited by specialised HSP outpatient clinics in Bochum,
Kiel, and Tübingen, Germany, in the context of the
German Network of Hereditary Movement Disorders
(GeNeMove). Diagnostic criteria for HSP included (i)
spastic paraparesis or spastic tetraparesis with legs earlier
and more severely affected than arms or (ii) spastic para-
paresis as early and prominent sign of a neurodegenerative
multisystem disease after exclusion of other causes. To ex-
clude secondary forms of spastic paraparesis standard
diagnostic procedures covered MRI of head and spine,
vitamin B12 and folic acid levels, very long chain fatty
acids (VLCFA), neurometabolic screening (Krabbe dis-
ease, metachromatic leukodystrophy, GM1-gangliosidosis,
GM2-gangliosidoses Tay Sachs and Sandhoff, Gaucher dis-
ease) and cerebrospinal fluid analysis. All participants gave
their written informed consent. The study was approved
by the ethics committee of the recruiting centres.
Mean age of patients at examination was 47.5 ± 14.9
years (13–80 years). Disease onset varied between 0 and
68 years (mean age at onset 29.6 ± 17.3 years), mean dis-
ease duration was 18.0 ± 13.1 years (0–64 years). At
examination 35 patients used a walking aid, 15 patients
were wheelchair-bound.
Family history was positive in 55 of 109 families, in-
cluding 46 families with autosomal dominant (42%) and
9 families with autosomal recessive (8%) disease inherit-
ance. The diagnosis was genetically confirmed in 54 of
128 cases (46%). In addition to 35 cases with SPG4 the
following genotypes were identified: SPG3 (1), SPG5 (3),
SPG7 (3), SPG8 (1), SPG10 (1), SPG11 (6), and SPG15
(4). SPG4 mutations were excluded in 34 of the 74 cases
with unknown genotype (“non-SPG4 patients”).
Clinical severity was assessed by Spastic Paraplegia
Rating Scale (SPRS) [17]. The sum of the point values
for spasticity of hip adductor muscles, spasticity of knee
flexion, weakness of hip abduction, and weakness of foot
dorsiflexion were designated as “spastic subscore”. Pure
HSP was diagnosed if spastic paresis was accompanied
by impaired vibration sense and/or urinary urgency only
(56% of patients in our cohort). Presence of other add-
itional signs or symptoms resulted in classification as
complicated HSP (44% of our patients) [2]. Peripheralmotor neuropathy was clinically assumed by summing
up the number of the following items: loss of muscle
stretch reflexes to the upper limbs, loss of muscle stretch
reflexes to the lower limbs, muscle wasting of the upper
limbs, and muscle wasting of the lower limbs. Analo-
gously, the sensory system was rated to be clinically af-
fected (“clinical sensory deficit”) by summing up the
number of the following affected parameters: touch
sense, pinprick sensation, vibration sensation (< 6/8),
joint position sense, and temperature discrimination.
Electrophysiological techniques
Motor evoked potentials (MEPs) were measured to the
right and left abductor digiti minimi (ADM) and abductor
hallucis (AH) muscle after muscle activation. For total
motor conduction time (TMCT) stimulus was given with
a circular coil over the vertex and stimulus intensity was
chosen 20% above motor threshold at rest. Peripheral
motor conduction time (PMCT) was calculated with the
shortest F wave latency out of 16 trials after supramaximal
stimulation of the ulnar nerve at the wrist or the tibial
nerve at the medial malleolus respectively: PMCT = [(dis-
tal motor latency + F wave latency)/2] +1. Central motor
conduction time CMCT = TMCT – PMCT.
Nerve conduction studies (NCS) with surface electrodes
were performed on the right side, except local problems
would have falsified the results. Motor NCS were per-
formed of the ulnar and tibial nerve. Amplitudes of com-
pound motor action potentials (CMAPs) were measured
peak to peak. Stimulus intensity was increased in 5 mA
steps to maximum response. Stimulus duration was ad-
justed 0.2 ms, and increased, if supramaximal stimulation
was not reached otherwise. Recording electrode was placed
over the abductor digiti minimi and abductor hallucis
muscle respectively, distal stimulation was performed with
the electrode 5 and 7 cm proximal to the recording elec-
trode and proximal stimulation with the electrode at the
elbow distal the sulcus ulnaris and at the popliteal fossa
respectively.
Sensory NCS were recorded from the radial and sural
nerve with antidrome technique and supramaximal sti-
mulus intensity. Amplitudes of sensory nerve action po-
tentials (SNAPs) were measured baseline to peak. The
recording electrode was placed over the first dorsal
spatium interosseum and behind the external malleolus
respectively, stimulation electrode 15 cm and 14 cm
proximal to the recording electrode respectively. Electro-
physiologically peripheral neuropathy was assumed, if
NCS were abnormal in two or more nerves.
Somato-sensory evoked potentials (SSEPs) of median
and tibial nerve were acquired using surface electrodes
over C3’/C4’ and Cz’ (3 cm posterior to Cz) respectively,
and referred to Fpz. Electrode impedances were less than
5 kOhm. The constant current stimuli were rectangular
Figure 1 Correlation of central motor conduction time (CMCT)
to arm and leg. CMCT to the abductor digiti minimi muscle (ADM)
and abductor hallucis muscle (AH) is correlated (r = 0.595; p <
0.0001). In (A) results for the left-hand side, in (B) for the right-hand
side are shown. Patients with SPG4 mutations are indicated by red
triangles, other patients by black squares.
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per second at the medial side of the ankle and the wrist,
respectively. Stimulus intensity was adjusted to produce
a small muscle twitch. Overall bandpass was chosen 1 to
1500 Hz, analysis time was 100 ms. Two series of 200
potentials were recorded, averaged, superimposed, and
checked for reproducibility. The latency was measured
at Erb and N20 for median nerve, and L1 and P40 for
tibial nerve.
Normal values and statistical analysis
Standard procedures and normal values were elaborated
for NCS, MEP and SSEP in Tübingen, and transferred to
the centres in Bochum and Kiel. Extreme values were
checked for plausibility. Statistical analyses were performed
using IBM SPSS Statistics 20.0 software (IBM Deutschland
GmbH, Ehningen, Germany). Mean and standard deviation
are given. Parameters were either normally distributed or
slightly skewed (< 3.12), therefore parametric testing was
applied. For continuous variables bivariate correlations
were performed using the Pearson correlation coefficient,
for categorised variables using Kendalls Tau-b. Significance
was tested by one- or two-sided ANOVA, as appropriate.
An alpha level of p < 0.05 was considered to be significant.
Results
Clinical characterisation
In our cohort, disease severity assessed by SPRS reached
1 to 44 points (mean 17.8 ± 8.5 points); the spastic items
(“spastic subscore”, as described in Methods section)
ranged from 0 to 14 points (mean 4.6 ± 2.5 points). A
clinical sensory deficit was obvious in 56% of patients
(including patients with only vibration sense deficits), a
peripheral motor neuropathy was clinically suspected in
18% of patients, and 22% of patients had upper limb
spasticity in addition to spastic paraparesis.
Central motor pathways
CMCT to upper and lower limbs correlated with each
other (r = 0.595; p < 0.0001; see also Figure 1). Age had
no influence on CMCT.
Although pyramidal tract affection to the legs is an ob-
ligatory feature and the primary hallmark of HSP, motor
evoked potentials (MEPs) to the legs were normal in 27%
of patients. 37% presented with prolonged CMCT. In 36%
of patients no MEP could be evoked. CMCT to the legs
correlated with total SPRS score (r = 0.176; p < 0.028) and
spastic subscore (r = 0.241, p < 0.005, see also Figure 2).
Pathologic CMCT to lower limbs correlated with disease
duration (r = 0.231; p < 0.009).
In contrast, MEPs to the arms were surprisingly often
pathologic in HSP (32%), including 28% with prolonged
and 4% with not evocable MEPs. CMCT to the arms
correlated with total SPRS score (r = 0.234, p < 0.005)and spastic subscore (r = 0.300, p < 0.0001), but not with
disease duration.
A subgroup of seven patients (6%) showed very pro-
nounced CMCT prolongation to the arms (≥ 15.0 ms,
normal < 8.6 ms), and 17 (14%) to the legs (≥ 25.0 ms,
normal < 16.1 ms) suggestive of a demyelinating process.
Most of the patients were of unknown genotype, in two
patients a mutation was found in the SPG5 and SPG7
gene respectively. In none of these patients a SPG4 mu-
tation was found.
Sensory pathways
SSEPs were available for median (n=47) and tibial (n=86)
nerve stimulation. As peripheral stimulation at Erb and L1
was not available in several patients due to spastic reac-
tions to repetitive stimulation, we included only cortical
latencies in the analysis. Cortical latencies (N20) of median
nerve SSEPs were prolonged in 9% and missing in 9%.
Cortical latencies (P40) of tibial nerve SSEPs were delayed
in 7% and missing in 29%. P40 latencies correlated with
clinical sensory deficit (r = 0.314; p < 0.001), whereas for
N20 latency significance was missed (r = 0.264; p < 0.063).
Sensory nerve conduction velocities (SNCVs) correlated
with cortical SSEP latencies in upper and lower limbs:
Radial NCV correlated with N20 latency (r = 0.521;
Figure 2 Conduction in motor evoked potentials correlate with
clinical disease severity. In (A) Spastic Paraplegia Rating Scale
(SPRS) [17], in (B) spastic subscore is correlated with central motor
conduction time (CMCT) to the right abductor hallucis muscle (AH)
(SPRS: r = 0.176; p < 0.028. Spastic subscore: r = 0.241, p < 0.005).
Patients with SPG4 mutations are indicated by red triangles, other
patients by black squares. Results to the left leg correlated
accordingly; data not shown.
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p < 0.001). The validity of the correlation of SNCV and
SSEP is limited as cortical latencies of SSEP also include
peripheral nerve conduction time.Peripheral nerve involvement
NCS were abnormal in 75 patients (59%). In 17% of pa-
tients only sensory nerves, in 16% only motor nerves
and in 25% both sensory and motor nerves were af-
fected. In 15% of patients only legs were affected, in 14%
only arms, and in 30% of patients both legs and arms
were involved. Details of nerve conduction abnormalities
are given in Table 1.Table 1 Peripheral nerve involvement assessed by nerve cond
Nerve N Percentage of patients w
NCS DML
Motor tibial nerve 128 33.9% 17.2%
Motor ulnar nerve 128 23.8% 11.8%
Sensory sural nerve 128 24.2% -
Sensory radial nerve 100 36.0% -
N: number of patients examined, DML: distal motor latency, NCV: nerve conductionAbnormal distal motor latency (DML), NCV or F wave
latency in combination with normal amplitudes were
regarded as hint for demyelinating affection, whereas am-
plitude reduction and normal conduction parameters were
interpreted as axonal involvement. According to this clas-
sification, 24% of patients presented with demyelinating,
5% with axonal and 6% with mixed neuropathy of tibial
nerves, whereas in 66% neurography of tibial nerve was
normal. In ulnar nerve 23% of patients showed a demye-
linating and 1% a mixed pattern. In sural nerves, type of
damage was demyelinating in 9% of patients, axonal in 9%,
and mixed in 6%. In radial nerves 5% of patients presented
with demyelinating and 18% with axonal type of damage,
and 12% a mixed affection.
Amplitudes of CMAPs and SNAPs were inversely corre-
lated with age, so the correlations of NCS were analysed
with age as confounding factor. Central and peripheral
conduction velocities correlated both in upper and lower
limbs (Figure 3): NCV and F wave latency of the ulnar
nerve correlated with CMCT to the arm (r = 0.249; p <
0.004 and r = −0.280; p < 0.002, respectively). Accordingly,
NCV and F wave latency of the tibial nerve correlated with
CMCT to the leg (r = 0.463; p < 0.0001 and r = −0.270;
p < 0.09, respectively).
Clinical signs of peripheral nerve involvement corre-
lated with electrophysiological peripheral neuropathy
(r = 0.362; p < 0.0001). Clinical sensory deficits corre-
lated with pathologic NCS of the sural nerve (r = 0.291;
p < 0.004).
Subgroup analysis of genetically confirmed HSP patients
SPG4 patients
A clinically “pure” HSP form was found more often in
SPG4 patients in comparison to patients with SPG4 ex-
cluded (non-SPG4 patients) (60% vs. 36%, p = 0.052). Nys-
tagmus, limb ataxia, gait ataxia, impaired pinprick
sensation, impaired joint position sense, and clinical signs
for spasticity of the arms were significantly rarer in SPG4
patients (p < 0.05, respectively).
In most SPG4 patients CMCT was normal both to arms
(mean 5.1 ± 1.5 ms) and legs (14.1 ± 3.9 ms). In contrast,
non-SPG4 patients presented with significantly longer
CMCT to arms (mean 6.9 ± 2.6 ms, p < 0.001) and legs
(mean 18.2 ± 7.3 ms, p < 0.016; see also Figures 1 and 2).uction studies (NCS) in HSP patients
ith abnormal
NCV Amplitude F wave latency
22.7% 10.2% 8.7%
4.7% 0.8% 15.9%
21.9% 14.8% -
17.0% 31.0% -
velocity.
Figure 3 Correlation of central and peripheral motor damage. (A and B) Nerve conduction velocity (NCV) and F wave latency of the ulnar
nerve correlated with central motor conduction time (CMCT) to the abductor digiti minimi muscle (ADM) (r = 0.249; p < 0.004 and r = −0.280;
p < 0.002, respectively). (C and D) Accordingly, NCV and F wave latency of tibial the nerve correlated with CMCT to abductor hallucis muscle
(AH) (r = 0.463; p < 0.0001 and r = −0.270; p < 0.09, respectively). Patients with SPG4 mutations are indicated by red triangles, other patients by
black squares.
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the type of mutation. Patients with SPG4 missense muta-
tions had significantly shorter CMCTs to legs in compari-
son to patients with SPG4 splice site mutations, premature
stop codon or in-frame exon deletions (10.5 ± 1.3 ms vs.
13.9 ± 3.7 ms, p < 0.013). In SPG4 patients nerve conduc-
tion abnormalities of tibial and ulnar motor nerves were
present in 20.0% and 8.8% respectively. Sensory sural
and radial nerves were pathologic in 20.0% and 24.1%
respectively.Other genetically defined HSP forms
Genetic testing revealed 19 patients with mutations in
HSP genes other than SPG4 (see Methods section). In
the majority of these patients CMCT to the legs was
prolonged. Details of motor evoked potentials in differ-
ent genotypes are given in Table 2. Nerve conduction
studies were normal in the single SPG3 patient whereas
SPG5, SPG8 and SPG10 patients presented with mild
motor neuropathy and patients with SPG11 and SPG15
had sensory-motor neuropathy. In SPG7 patients sensory
tracts were affected. Detailed results of electrophysio-
logical testing are presented in Table 3.Discussion
Comprehensive electrophysiological analyses in this up
to date largest cohort of HSP patients revealed not only
prominent affection of corticospinal tracts to the legs
but also in many cases to the arms as well as affection of
sensory systems and peripheral nerves. This affirms that
HSP is not a pure upper motoneuron disease but fre-
quently affects other long fibre tracts.
Some authors regard spread of corticospinal tract af-
fection to the arms as an indicator of primary lateral
sclerosis rather than HSP [18]. Here we show that
according to MEP criteria arms are involved in about
one third of HSP patients including many patients with
genetically confirmed diagnosis carrying mutations in
well-established HSP genes. Our results are in accord-
ance with smaller studies finding prolonged CMCT to
legs in the majority of cases and affection of arms in up
to 32% [8-10]. The results are consistent with a length-
dependent neurodegenerative process.
Conversely, CMCT to legs was normal in about 27%
of HSP patients despite unequivocal clinical signs of
corticospinal tract affection. This may be explained by a
primarily axonal type of damage seen in several subtypes
of HSP or alternatively by a selective affection of thinner
Table 2 Transcranial magnetic stimulation and sensory
evoked potentials in genetically defined subtypes of HSP
Genotype CMCT ADM
(in ms)
CMCT AH
(in ms)
N20 latency
(in ms)
P40 latency
(in ms)
SPG3 0/1 1/1 n.d. n.d.
6.4 29.0
SPG4 0/35 17/35 0/12 6/24
5.1 ± 1.4 14.1 ± 3.9 19.9 ± 1.1 42.6 ± 3.6
3.0-8.4 7.0-23.0 18.0-21.8 37.8-52.6
SPG5 1/3 3/3 2/2 2/2
7.8 ± 2.5 24.4 ± 5.5 - -
5.2-10.6 19.0-29.0 - -
SPG7 0/3 2/3 0/1 1/2
4.4 ± 1.5 18.6 ± 6.5 20.9 46.3 ± 3.0
2.4-6.4 13.8-25.6 - 42.8-49.6
SPG8 1/1 1/1 0/1 1/1
- - 19.3 49.7
SPG10 0/1 1/1 0/1 1/1
3.9 - 19.0 -
SPG11 1/6 4/6 0/2 2/4
4.9 ± 1.0 13.3 ± 1.4 20.0 ± 0.6 43.2 ± 0.7
3.6-6.0 12.0-15.2 19.0-20.5 42.0-44.6
SPG15 3/4 4/4 n.d. 1/1
7.6 ± 2.4 - 50.8
4.4-10.2 - -
Threshold
value
< 8.6 < 16.0 < 23.3 < 49.0
For each genotype is given: in the first row the number of pathologic results
in the number of individuals examined, in the second row mean and standard
deviation, and in the third row the range of values. CMCT: central motor
conduction time, ADM: abductor digiti minimi, AH: abductor hallucis, N20:
primary cortical negativity of somatosensory potentials with median nerve
stimulation, P40: primary cortical positivity of somatosensory potentials with
tibial nerve stimulation, n.d.: not done.
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spinal or vestibulo-spinal tracts) that spares the fastest
conducting thick fibres investigated by transcranial mag-
netic stimulation.
Additionally, we show that HSP in many cases is not
restricted to the motor system but affects the sensory
system as well. Abnormal cortical potentials in 38% of
tibial nerve SSEPs prove sensory system involvement in
a substantial portion of HSP patients. Similarly, sensory
NCS were abnormal in about one third of HSP patients.
Previous studies included only small numbers of patients
and led to variable results [9,12-14].
Here we screened a large HSP cohort that was not se-
lected for clinical signs of peripheral neuropathy and
found involvement of peripheral motor nerves in 44% of
patients. Tibial nerves were more frequently impaired
than ulnar nerves reflecting the more severe affection of
longer motor axons to the legs. The affection of upperand lower motoneurons may be of special importance in
the differential diagnosis between HSP and amyotrophic
lateral sclerosis (ALS). Although we did not perform
electromyography (EMG) and cannot differentiate be-
tween neuronal and axonal damage, it becomes clear
that the combination of upper and lower motor tract af-
fection per se is not indicating ALS but is a rather fre-
quent constellation in HSP as well. Recent data suggest
a continuum in motoneuron disorders; several genes can
underlie different phenotypes, resembling ALS, HSP
and HM(SA)N respectively (reviewed in [19]), e.g. Alsin
(ALS2) [20-22], Senataxin (ALS4) [23,24], NIPA1 (SPG6,
NIPA1 repeat expansions associated with ALS) [25,26],
BSCL2 (SPG17, HMSN V) [27-29], Atlastin-1 (SPG3,
HSN-I) [30-32], KIF1A (SPG 30, HSAN-II) [33,34], and
REEP1 (SPG31, dHMN-V) [35,36].
Electrophysiologically, there is an interrelation be-
tween central and peripheral damage. This could indi-
cate a common length-dependent disease mechanism
in several long fibre tracts. Hereby, electrophysiological
analyses may provide a window into pathomechanisms
that alter conduction parameters in long fibre tracts in a
genotype specific manner.
The affection of long fibre tracts is also seen in neuro-
pathological examinations. In pure HSP forms degener-
ation of the corticospinal tract and the posterior column
was compatible with a dying-back axonopathy [37-39].
This result was also confirmed in genetically proven
cases of SPG4 [40,41]. In complicated forms pathology
shows more widespread neurodegeneration also affecting
the thalamus, brainstem nuclei and the cerebellum [42].
Disturbance of axonal transport as in SPG4 and SPG10
with mutations in Spastin affecting microtubule severing
and in KIF5A affecting the motor of anterograde axonal
transport may go along with an axonal type of conduction
disturbance [41,43,44]. In accordance with this patho-
physiological assumption and previous studies [11,15], in
our cohort of SPG4 patients MEPs to the arms were
normal. As a rule of thumb, massively elongated CMCT
(arms ≥ 15.0 ms, legs ≥ 25.0 ms) argue against a SPG4
genotype. But even within the group of SPG4 patients a
considerable variability of CMCTs with reduced ampli-
tudes and prolonged latencies were reported [45]. On the
basis of the results in two SPG4 families a role of the mu-
tation type was proposed [16]. In our large cohort of 35
SPG4 patients MEP latencies in patients with SPG4 mis-
sense mutations were significantly shorter in comparison
to SPG4 splice site mutations, premature stop codons or
in-frame exon deletions.
Our data represent a cross-sectional analysis. It will be
interesting to learn about the dynamics of electrophysio-
logical abnormalities in HSP. At present, it remains open
to speculation whether motor and sensory, central and
peripheral systems are affected at the same time and
Table 3 Nerve conduction studies in genetically defined subtypes of HSP
Genotype Tibial nerve Ulnar nerve Sural nerve Radial nerve
DML
(in ms)
CMAP
(in mV)
MNCV
(in m/s)
FWL
(in ms)
DML
(in ms)
CMAP
(in mV)
MNCV
(in m/s)
FWL
(in ms)
SNAP
(in μV)
SNCV
(in m/s)
SNAP
(in μV)
SNCV
(in m/s)
SPG3 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
3.6 14.6 52 48.8 2.2 10.1 61 28 24.0 57 20.3 57
SPG4 6/35 0/35 2/35 1/35 1/34 0/34 1/34 1/34 4/35 6/35 5/29 2/29
4.3±0.8 18.7±6.8 47.2±5.7 51.7±4.9 2.4±0.4 15.9±3.2 60.8±4.5 27.6±2.3 11.1±7.8 47.7±7.0 22.2±7.0 62.0±5.0
3.0-6.5 7.3-35.0 36-69 43.0-66.3 1.7-3.2 6.8-22.7 50-69 23.2-33.7 0–37.7 34-64 10.9-35.2 50-73
SPG5 0/3 0/3 0/3 0/3 1/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
3.8±0.9 26.6±11.0 46.0±5.0 48.7±6.5 2.8±0.6 15.5±4.4 66.7±3.2 24.3±2.7 28.7±13.1 46.7±8.1 32.9±2.6 64.3±4.2
2.9-4.7 17.3-38.7 41-51 41.2-53.0 2.1-3.3 12.8-20.5 63-69 21.6-27.0 14.6-40.5 41-56 30.6-35.7 61-69
SPG7 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
4.0±0.4 22.1±9.1 46.7±3.5 47.5±5.7 2.2±0.3 15.1±4.0 65.7±1.5 28.8±0.3 17.5±4.9 48.7±2.3 24.0±2.4 63.7±2.5
3.7-4.5 11.7-28.3 43-50 41.2-52.4 1.8-2.4 12.3-19.7 64-67 28.4-29.0 12.9-22.6 46-50 21.9-26.6 61-66
SPG8 0/1 0/1 1/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
3.2 10.2 37 54.3 2.4 16.1 59 28.3 26.0 43 19.7 59
SPG10 0/1 0/1 1/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1
4.2 22.1 40 51.4 2.5 11.4 51 27.2 5.9 52 23.1 61
SPG11 1/6 1/6 3/6 1/5 1/6 2/6 0/6 1/5 1/6 1/6 2/5 3/5
4.7±2.1 18.6±12.2 41.7±3.6 51.9±7.6 2.9±0.7 14.0±7.1 61.5±4.3 27.6±2.0 12.1±10.9 47.0±5.8 19.2±5.6 55.0±4.4
3.6-8.8 0.9-36.1 37-46 45.1-64.8 2.1-4.3 1.1-21.1 58-70 24.6-29.0 1.6-31.6 38-56 12.5-24.5 48-60
SPG15 0/4 0/4 3/4 0/4 0/4 0/4 0/4 2/4 1/4 1/4 1/3 1/3
4.3±1.0 8.8±3.8 38.3±5.7 56.9±5.4 2.7±0.2 14.2±2.3 55.3±4.6 30.3±2.8 7.1±3.7 47.5±13.9 18.6±6.0 56.3±2.9
2.8-5.0 5.8-14.3 30-43 49.0-61.0 2.4-2.8 11.6-16.4 51-61 26.1-32.2 2.9-11.9 31-65 11.7-22.4 53-58
Threshold value < 5.1 > 5.0 > 40 < 63.6 < 3.2 > 4.0 > 50 < 31.0 > 3.8 > 39 > 16.0 > 55
For each genotype is given: in the first row the number of pathologic results in the number of individuals examined, in the second row mean and standard
deviation, and in the third row the range of values. DML: distal motor latency, CMAP: compound motor action potential, MNCV: mean nerve conduction velocity,
FWL: F wave latency, SNAP: sensory nerve action potential, SNCV: sensory nerve conduction velocity.
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http://www.ojrd.com/content/8/1/158whether there is a linear or a non-linear progression of
electrophysiological abnormalities. Longitudinal studies
will help to assess electrophysiological parameters as po-
tential biomarkers of the neurodegenerative process.
Given the clinical variability of spasticity with tempe-
rature and seasons as well as symptomatic treatment,
and given the correlation of disease severity and MEP
abnormalities demonstrated in this study, electrophysio-
logical parameters may become important progression
markers in upcoming interventional trials.
Conclusions
HSP is considered an upper motoneuron disease primarily
affecting the longest fibres to the legs. Our clinical and
electrophysiological analysis suggests a more widespread
involvement of motor and sensory tracts in the central
and peripheral nervous system. Pronounced elongation of
MEPs favours against the most common form of HSP,
SPG4. As electrophysiological measures are independent
of symptomatic treatment they might become important
progression markers in upcoming HSP trials.Availability of supporting data
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